M&A

M&A

Biocon’s arm Syngene acquires US vaccine maker Emergent’s facility for $36.5 M

Business Line  

Syngene International, the contract research wing of Biocon Group, has acquired its first manufacturing facility in the US from Emergent Manufacturing Operations Baltimore, a subsidiary of Emergent BioSolutions . The company has invested around USD 50 million, including the cost of acquisition, i.e., USD 36.5 million, and expenses to make the facility operational. The sale is expected to close this month.The facility is equipped with multiple monoclonal antibody (mAbs) manufacturing lines. The site is expected to increase Syngene’s total single-use bioreactor capacity to 50,000L for large molecule discovery, development, and manufacturing services.Emergent is a global specialty life sciences company that develops, manufactures, and stores medical countermeasures. It specializes in developing vaccines, therapeutics, and devices.